Clinical trials: Metastatic Squamous Cell Carcinoma
Squamous Cell Carcinoma of Head and Neck
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
The primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line (1L) treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the…
- Trial name
- SKYSCRAPER-09 (NCT04665843)
- Testing
- Atezolizumab, Tiragolumab
- Where
- 47 sites in United States, Czechia and 11 more
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT02677597
- Testing
- Cisplatin Combined With S-1, Cisplatin Combined With Paclitaxel
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Fudan University
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer
The goal of this clinical research study is to learn if utomilumab, when given with ISA101b, is able to shrink or slow the growth of tumors in patients with incurable HPV+ oropharyngeal squamous cell carcinoma.
- Conditions
- Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
- Trial name
- NCT03258008
- Testing
- Utomilumab, ISA101b
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of Oral Cavity
Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+
Primary Objective: To determine the 2-year distant failure rate of maintenance tegafur-uracil in patients with squamous cell carcinoma of oral cavity with extracapsular spreading of lymph nodes.
- Trial name
- NCT03121313
- Testing
- tegafur-uracil
- Where
- Taiwan
- Volunteers
- 68 people
- Sponsor
- Chang Gung Memorial Hospital
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease
This early phase I trial studies how well fluciclovine F18 positron emission tomography (PET)/computed tomography (CT) works in identifying the origin of head and neck squamous cell carcinoma in patients with cancer that has…
- Trial name
- NCT03868020
- Testing
- Computed Tomography, Fluciclovine F18, Positron Emission Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Lung Carcinoma
TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
This is a non-randomized, open label, sequentially enrolling phase II study with a Simon two-step enrollment design to evaluate the activity of TAS-102 in previously treated unresectable or metastatic squamous non-small cell…
- Trial name
- NCT02920476
- Testing
- TAS-102
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Florida
Head and Neck Cancer
Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- DORA (NCT01313390)
- Testing
- docetaxel, everolimus, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- University College, London
Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
Vaccination With Flt3L, Radiation, and Poly-ICLC
This is a combination of 4 therapies, three of which are used to treat a single "target site" of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into the blood stream (intravenous or "IV"). 1.
- Conditions
- Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03789097
- Testing
- Pembrolizumab, Flt3L, Radiation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell…
- Trial name
- MORALE-HN01 (NCT07662720)
- Testing
- axelopran, Pembolizumab
- Volunteers
- 18 people
- Sponsor
- Glycyx Therapeutics
Head and Neck Cancer
Anti-platelet + Pembro for H&N Tumors
The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous…
- Trial name
- NCT03245489
- Testing
- Pembrolizumab, Clopidogrel, acetylsalicylic acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Head and Neck Cancer
Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
RATIONALE: Drugs used in chemotherapy, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells.
- Trial name
- NCT00079079
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 4 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer, Non-Small Cell
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis.
- Trial name
- NCT04581824
- Testing
- Dostarlimab, Pembrolizumab, Chemotherapy
- Where
- 58 sites in United States, Argentina and 10 more
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline
Uterine Neoplasms, Uterine Cervical Neoplasms
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the…
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
- Trial name
- NCT04579380
- Testing
- tucatinib, trastuzumab, fulvestrant
- Where
- 108 sites in United States, Belgium and 6 more
- Volunteers
- 217 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Squamous Cell Carcinoma of the Penis
Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)
The purpose of this study is to evaluate the efficacy and safety of Cetuximab in metastatic penile carcinoma
- Trial name
- PENILANE (NCT02014831)
- Testing
- Cetuximab, TIP
- Where
- 7 sites in France
- Sponsor
- Centre Leon Berard
Carcinoma, Non-Small-Cell Lung
CIETAI and Sequential Radiotherapy in Squamous Lung Cancer
Central-type lung cancer refers to lung malignancies originating from the segmental bronchi and above. The most common tissue type is squamous cell carcinoma.
- Trial name
- NCT05892237
- Testing
- bronchial artery interventional therapy, Chemotherapy drug, IMRT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Dong Wang
Lung Cancer
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054392
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 57 sites in United States
- Sponsor
- Fox Chase Cancer Center
Carcinoma, Non-Small-Cell Lung
GIOTRIF rPMS in Korean Patients With NSCLC
To monitor the safety profile and efficacy of GIOTRIF® (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
- Trial name
- NCT02285361
- Testing
- GIOTRIF 20mg, GIOTRIF 40mg, GIOTRIF 30mg
- Where
- South Korea
- Volunteers
- 1,272 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Currently, there is a lack of high-quality clinical evidence for subsequent treatment options for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) after first-line treatment, especially for subsequent treatment…
- Trial name
- NCT06494995
- Testing
- Cadonilimab, Low-dose radiotherapy, SBRT
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Fudan University
Esophageal Tumor, Metastatic Esophageal Squamous Cell Carcinoma
The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma
This is a single institutional, single arm, open labeled phase II study to assess the overall radiographic response of adding Avelumab to chemotherapy and palliative radiotherapy in patients with metastatic advanced esophageal…
- Trial name
- NCT03800953
- Testing
- Avelumab
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.